Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers

Psychoneuroendocrinology
Johan DahlHeidi Ormstad

Abstract

It has been suggested that the development of depressive symptoms as a result of cytokine therapy is attributable to cytokine-induced elevated activity of the kynurenine pathway. The few studies of this mechanism in patients with common major depressive disorder (MDD) have yielded inconsistent results. The aim of the present study was to identify markers of the kynurenine pathway in a clinical MDD sample with increased cytokine levels. Fifty medication-free MDD patients with a depressive episode and 34 healthy controls were included at baseline; the patients were followed for 12 weeks. Before initiating treatment, the patients were diagnosed and assessed for depressive symptoms and their blood was analyzed for tryptophan and its metabolites in the kynurenine pathway. The clinical assessments and metabolite measurements were repeated after 12 weeks of "treatment as usual". We did not find significant elevation of kynurenine plasma markers in patients with a depressive episode compared to healthy controls, despite elevated cytokine levels in the patients. Clinical depression scores were significantly reduced after 12 weeks, but no significant change in the plasma kynurenine pathway plasma markers was observed. The obtained result...Continue Reading

References

Aug 1, 1991·Medical Hypotheses·R S Smith
Mar 1, 1980·Neurochemical Research·E M Gál, A D Sherman
Oct 16, 1996·Psychiatry Research·A SluzewskaK Wiktorowicz
Dec 1, 1996·The Biochemical Journal·M P HeyesS P Markey
Mar 29, 2001·The New England Journal of Medicine·D L MusselmanA H Miller
Aug 9, 2006·Archives of General Psychiatry·Carlos A ZarateHusseini K Manji
Sep 6, 2006·Journal of Affective Disorders·Aye-Mu MyintBrian Leonard
Nov 8, 2006·Brain, Behavior, and Immunity·Robert Dantzer, Keith W Kelley
Apr 17, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yong-Ku KimJung-Bum Kim
Aug 8, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N M SimonK K Wong
Apr 25, 2008·The New England Journal of Medicine·Andrea SainiAlfredo Berruti
Apr 22, 2010·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Vilma GabbayLeonard Liebes
Nov 3, 2010·Psychoneuroendocrinology·Robert DantzerKeith W Kelley
Dec 21, 2010·Current Immunology Reviews·Brian E Leonard
Jan 25, 2011·Expert Opinion on Therapeutic Targets·Kanwaljit ChopraAnurag Kuhad
May 25, 2011·Brain, Behavior, and Immunity·M Elizabeth SubletteTeodor T Postolache
Jun 12, 2012·Brain, Behavior, and Immunity·Martina M HughesThomas J Connor
Jan 10, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sophie ErhardtLena Brundin
Mar 21, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Adam K WalkerRobert Dantzer
Apr 23, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michel Hamon, Pierre Blier
Aug 31, 2013·Journal of Molecular Neuroscience : MN·Heidi OrmstadLeiv Sandvik
Nov 5, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Aye-Mu Myint, Yong-Ku Kim

❮ Previous
Next ❯

Citations

Jan 18, 2016·The International Journal of Neuropsychopharmacology·Martina M HughesAndrew Harkin
Oct 16, 2015·Medical Hypotheses·Heidi Ormstad, Grethe Eilertsen
Aug 11, 2015·Acta Psychiatrica Scandinavica·L BrundinT T Postolache
Sep 9, 2015·Frontiers in Psychiatry·Jennifer M Parrott, Jason C O'Connor
Mar 31, 2016·The International Journal of Neuropsychopharmacology·Jennifer L Remus, Robert Dantzer
May 31, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Heidi OrmstadMichael Maes
Apr 5, 2016·PloS One·Isak SundbergJanet L Cunningham
Apr 12, 2017·Translational Psychiatry·T D GouldT T Postolache
Dec 30, 2016·Neuroscience Bulletin·Jiangling JiangChunbo Li
Feb 27, 2019·Psychopharmacology·Luca SforziniCarmine Maria Pariante
Jul 6, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lena BrundinKeerthi Thirtamara Rajamani
Mar 9, 2019·Frontiers in Psychiatry·Eva Z ReininghausBernd Reininghaus
Aug 28, 2020·Frontiers in Psychiatry·Paria Baharikhoob, Nathan J Kolla
Oct 1, 2020·International Journal of Clinical Practice·Masum ÖztürkÖmer Aydemir
May 25, 2021·Neuroscience and Biobehavioral Reviews·Samara J BrownKelly A Newell
Jun 3, 2021·International Journal of Molecular Sciences·Ferenc ZádorLászló Vécsei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.